Ultragenyx Pharmaceutical Inc. (RARE)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch RARE
See up to 3 months of RARE. The 7-day demo opens the 1M and 3M ranges and puts RARE on your watchlist.
Start 7-day demoLatest RARE insider trades
Theodore Alan Huizenga - OfficerOpen-market sale$17K- Theodore Alan Huizenga - Officer
About Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. files with the SEC under CIK 0001515673 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
RARE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 4 | 8,040 | $184K |
RARE insider transactions (Form 4)
5048 Form 4 filings on record, the earliest from Oct 11, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Theodore Alan Huizenga - Officer | Open-market sale | Common Stock | 1,283 | $13.57 | $17K | |
| Theodore Alan Huizenga - Officer | Open-market sale | Common Stock | 161 footnote F1 | $13.99 | $2K | |
| ||||||
 Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 1,900 | $24.92 | $47K | |
 Howard Horn - Officer | Open-market sale | Common Stock | 4,696 | $24.92 | $117K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,698 | $33.13 | $156K | |
| Corazon (Corsee) D. Sanders | Open-market sale | Common Stock | 2,000 | $25.05 | $50K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 1,899 | $24.62 | $47K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,653 | $23.77 | $111K | |
| Matthew K. Fust | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Matthew K. Fust | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
| Shehnaaz Suliman | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Shehnaaz Suliman | Open-market sale | Common Stock | 5,740 | $25.12 | $144K | |
| Shehnaaz Suliman | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
 Amrit Ray | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Amrit Ray | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
| Corazon (Corsee) D. Sanders | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Corazon (Corsee) D. Sanders | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
 Michael Narachi | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Michael Narachi | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
| Daniel G. Welch | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Daniel G. Welch | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
 Deborah Dunsire | Grant or award | Common Stock | 7,751 footnote F1 | $0.00 | - | |
| Deborah Dunsire | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| ||||||
| Eric Crombez - Officer | Open-market sale | Common Stock | 344 footnote F1 | $24.96 | $9K | |
| ||||||
| Howard Horn - Officer | Open-market sale | Common Stock | 4,683 | $24.90 | $117K | |
| Theodore Alan Huizenga - Officer | Grant or award | Common Stock | 20,241 footnote F1 | $0.00 | - | |
| Theodore Alan Huizenga - Officer | Grant or award | Stock Option (Right to Buy) | 7,348 | $0.00 | - | |
| ||||||
| Emil D. Kakkis - Officer | Grant or award | Common Stock | 76,745 footnote F1 | $0.00 | - | |
| Emil D. Kakkis - Officer | Grant or award | Stock Option (Right to Buy) | 132,693 | $0.00 | - | |
| ||||||
| Dennis Karl Huang - Officer | Grant or award | Common Stock | 23,116 footnote F1 | $0.00 | - | |
| Dennis Karl Huang - Officer | Grant or award | Stock Option (Right to Buy) | 79,936 | $0.00 | - | |
| ||||||
 John Richard Pinion - Officer | Grant or award | Common Stock | 23,116 footnote F1 | $0.00 | - | |
| John Richard Pinion - Officer | Grant or award | Stock Option (Right to Buy) | 79,936 | $0.00 | - | |
| ||||||
| Karah Herdman Parschauer - Officer | Grant or award | Common Stock | 28,895 footnote F1 | $0.00 | - | |
| Karah Herdman Parschauer - Officer | Grant or award | Stock Option (Right to Buy) | 49,960 | $0.00 | - | |
| ||||||
| Erik Harris - Officer | Grant or award | Common Stock | 28,895 footnote F1 | $0.00 | - | |
| Erik Harris - Officer | Grant or award | Stock Option (Right to Buy) | 49,960 | $0.00 | - | |
| ||||||
| Eric Crombez - Officer | Grant or award | Common Stock | 34,674 footnote F1 | $0.00 | - | |
| Eric Crombez - Officer | Grant or award | Stock Option (Right to Buy) | 59,952 | $0.00 | - | |
| ||||||
| Howard Horn - Officer | Grant or award | Common Stock | 34,674 footnote F1 | $0.00 | - | |
| Howard Horn - Officer | Grant or award | Stock Option (Right to Buy) | 59,952 | $0.00 | - | |
| ||||||
| Howard Horn - Officer | Open-market sale | Common Stock | 4,683 | $20.97 | $98K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 6,018 | $21.40 | $129K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 3,508 | $22.67 | $80K | |
| John Richard Pinion - Officer | Grant or award | Common Stock | 11,137 footnote F1 | $0.00 | - | |
| John Richard Pinion - Officer | Open-market sale | Common Stock | 10,029 footnote F2 | $22.80 footnote F3 | $229K | |
| ||||||
| Erik Harris - Officer | Open-market sale | Common Stock | 10,539 footnote F2 | $22.80 footnote F3 | $240K | |
| Erik Harris - Officer | Grant or award | Common Stock | 11,643 footnote F1 | $0.00 | - | |
| ||||||
| Emil D. Kakkis - Officer | Grant or award | Common Stock | 71,177 footnote F1 | $0.00 | - | |
| Emil D. Kakkis - Officer | Open-market sale | Common Stock | 54,404 footnote F2 | $22.80 footnote F3 | $1.24M | |
| ||||||
Item 1.01
Item 8.01
Item 8.01
Item 8.01
Recent RARE Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| THEODORE HUIZENGA | Officer | 1,283 | $17K | View on EDGAR | |
| HOWARD HORN | Officer | 4,696 | $117K |
Stock trades in RARE disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.Democrat, CA-31 | Purchase |
RARE insider trading FAQ
What is the latest insider trade for RARE?
Ultragenyx Pharmaceutical Inc. (RARE) had 4 insider filings in the last 90 days, with the most recent on 2026-09-15. The full record for RARE runs to 48 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RARE stock?
No insider purchases of RARE were filed in the last 90 days.
How many insiders are selling RARE stock?
4 insider sales of RARE were filed in the last 90 days, totaling $184K.
Where can I see RARE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RARE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Theodore Alan Huizenga view on EDGAR
- - Theodore Alan Huizenga view on EDGAR
- - Karah Herdman Parschauer view on EDGAR
- - Howard Horn view on EDGAR
- - Howard Horn view on EDGAR
- - Corazon (Corsee) D. Sanders view on EDGAR
- - Karah Herdman Parschauer view on EDGAR
- - Howard Horn view on EDGAR
- - Matthew K. Fust view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RARE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RARE with a 7-day demo
- RARE on your watchlist
- Every RARE Form 4 filing on record
- Up to 3 months of RARE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
